NCIt definition : A monoclonal antibody directed against growth/differentiation factor 15 (GDF-15; macrophage
inhibitory cytokine-1; MIC-1; non-steroidal anti-inflammatory drug-inducible gene-1;
NAG-1; placental transforming growth factor-beta; pTGFB; prostate-derived factor;
PDF; placental bone morphogenetic protein; PLAB), with potential antineoplastic activity.
Upon administration, ozekibart specifically targets, binds to and inhibits the activity
of GDF-15, thereby preventing the GDF-15-mediated inhibition of differentiation and
activation of human monocyte-derived dendritic cells (DCs) and T-cells. This may restore
immune cell infiltration into the tumor, leading to increases in T-cells and activated
DCs in the tumor microenvironment (TME). This enhances tumor cell killing and inhibits
tumor cell proliferation. GDF-15, a divergent member of the transforming growth factor-beta
(TGF-beta) superfamily of cytokines, is upregulated in tissue injuries and is secreted
by various tumors. Upregulation of GDF-15 is associated with immunosuppression in
the TME, drug resistance and poor prognosis.;
UNII : R0GA5221D4;
CAS number : 2539847-03-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2539847-03-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)